Drug intelligence / Profile preview

benglouting granules

Development stage: Unknown
Lead developer: Shuyang Chenggui Hospital
Administration: Oral

Overview

Benglouting granules is an investigational **traditional Chinese medicine herbal formula** in Phase 2 development for abnormal uterine bleeding, specifically menorrhagia associated with the traditional Chinese medicine blood-stasis syndrome. The granules contain five herbal or animal-derived medicinal materials: Pollen Typhae, Wulingzhi, Panax notoginseng, Angelica sinensis, and vinegar-processed Cyperus rotundus. It is intended to reduce uterine bleeding through traditional Chinese medicine principles of promoting blood circulation, resolving blood stasis, and hemostasis; a defined molecular target and modern pharmacologic mechanism have not been publicly established.

Other names: Beng LoutingBenglouting Granules崩漏停颗粒

Beyond the preview

Go deeper on benglouting granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benglouting granules.

Explore the full profile